Cubist is ditching 177 Optimer jobs after its $535M buyout

Just over a month after crossing the T's on a $535 million acquisition by Cubist Pharmaceuticals ($CBST), Optimer Pharmaceuticals is shedding 177 jobs in the U.S. and Canada, New Jersey's Star-Ledger reports. Massachusetts-based Cubist is shutting down Optimer's Garden State headquarters next year, according to the newspaper, and the company is working with affected employees to see if they might fit in elsewhere in its operations. Report

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.